Laekna, Inc.

Equities

2105

KYG5340S1093

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 am EDT			5-day change	1st Jan Change
6.74 ^HKD	-0.59%		-4.53%	-66.13%

May. 30	Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4%	MT
May. 30	Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer	CI

Laekna, Inc. Announces Resignation of Ji Dongmei as Non-Executive Director

September 29, 2023 at 04:40 am EDT

Laekna, Inc. announced that Ms. JI Dongmei has tendered her resignation, with effect from September 29, 2023, to resign from her position as a non-executive Director, due to her work commitments and time arrangement.

Latest news about Laekna, Inc.

Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4%	May. 29	MT
Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer	May. 29	CI
US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%	May. 22	MT
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer	May. 22	CI
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug	May. 10	MT
Lekna, Inc. Obtains IND Approval from the CDE for LAE102	May. 09	CI
Laekna Scores FDA Nod for Obesity Drug LAE102	Apr. 15	MT
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102	Apr. 15	CI
Laekna Shrinks Loss in Fiscal 2023	Mar. 27	MT
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug	Mar. 11	MT
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration	Mar. 11	CI
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities	Mar. 01	MT
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102	Feb. 29	CI
Laekna, Inc. Announces Management Changes	Feb. 02	CI
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34%	Jan. 28	MT
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China	Jan. 28	CI
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer	Jan. 15	CI
Laekna, Inc. Announces Executive Changes	Jan. 15	CI
326,372,350 Shares of Laekna, Inc. are subject to a Lock-Up Agreement Ending on 29-DEC-2023.	Dec. 28	CI
Laekna, Inc.(SEHK:2105) added to S&P Global BMI Index	Dec. 18	CI
Laekna Presents Data from Phase 1B Trial for Cancer Treatment	Dec. 11	MT
Laekna, Inc. Announces Presentation of the Study Results from Core Product Furesertib at the 2023 SABCS	Dec. 10	CI
Laekna, Inc. Announces Resignation of Ji Dongmei as Non-Executive Director	23-09-29	CI
Laekna Shrinks Loss in H1	23-08-25	MT

Chart Laekna, Inc.

Duration

Period

More charts

Company Profile

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LAEKNA, INC.	-66.13%	338M
VERTEX PHARMACEUTICALS INCORPORATED	+8.92%	114B
REGENERON PHARMACEUTICALS, INC.	+10.48%	105B
ARGENX SE	-3.14%	21.73B
BIONTECH SE	-6.45%	23.83B
GENMAB A/S	-10.67%	18.1B
WUXI APPTEC CO., LTD.	-42.36%	16.34B
BEIGENE, LTD.	-14.45%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+3.76%	13.75B
SAREPTA THERAPEUTICS, INC.	+28.94%	11.76B

Bio Therapeutic Drugs